Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Ojjaara (momelotinib) is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Momelotinib, ruxolitinib, and fedratinib demonstrated comparable efficacy in reducing spleen volume and total symptom scores in patients with myelofibrosis when used as first-line treatments.
• Pacritinib was less effective than ruxolitinib in treating splenomegaly in first-line therapy but appeared effective in second-line treatment after prior ruxolitinib exposure.
• The studies did not explicitly mention differences in effectiveness across specific populations or subgroups.
• Momelotinib demonstrated less toxicity related to erythrocytes and platelets compared to ruxolitinib and fedratinib, with a positive effect on anemia and reduced thrombopenia risk.
• There is no population types or subgroups information available in the reviewed studies.